Metastatic Adrenal Gland Pheochromocytoma

7 clinical trials · Condition

Record	Firm	Date
Testing the Addition of an Anticancer Drug, Olaparib, to the Usual Chemotherapy (Temozolomide) for Advanced Neuroendocrine Cancer (NCT04394858)	National Cancer Institute (NCI)	2021-03-17
Radioactive Drug (177Lu-DOTATATE) for the Treatment of Locally Advanced, Metastatic, or Unresectable Rare Endocrine Cancers (NCT04106843)	M.D. Anderson Cancer Center	2019-06-13
Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor (NCT02831179)	Vanderbilt-Ingram Cancer Center	2017-12-01
Lenvatinib in Treating Patients With Metastatic or Advanced Pheochromocytoma or Paraganglioma That Cannot Be Removed by Surgery (NCT03008369)	Mayo Clinic	2017-05-31
Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic (NCT02721732)	M.D. Anderson Cancer Center	2016-08-15
Cabozantinib S-malate in Treating Patients With Metastatic Pheochromocytomas or Paragangliomas That Cannot Be Removed by Surgery (NCT02302833)	M.D. Anderson Cancer Center	2015-02-17
Pazopanib Hydrochloride in Treating Patients With Advanced or Progressive Malignant Pheochromocytoma or Paraganglioma (NCT01340794)	National Cancer Institute (NCI)	2011-05-01

Every clearance here is in the API, with alerts when new ones post.